Tagrisso, un medicamento dirigido, podría ser un avance contra el cáncer de pulmón
LUNES, 6 de febrero de 2023 (HealthDay News) — El mejor tratamiento para una forma de cáncer de pulmón de origen genético sigue mostrando unos beneficios duraderos, según una nueva actualización de un ensayo clínico.Tagrisso (osimertinib) casi duplic…
Learn MoreTargeted Drug Tagrisso Could Be Advance Against Lung Cancer
MONDAY, Feb. 6, 2023 (HealthDay News) — The best treatment for a genetically driven form of lung cancer continues to show lasting benefits, a new clinical trial update shows.Tagrisso (osimertinib) nearly doubles disease-free survival in earlier-stage…
Learn MoreFDA Approves Second Alzheimer’s Drug, Despite Safety Concerns
FRIDAY, Jan. 6, 2023 (HealthDay News) — The U.S. Food and Drug Administration on Friday approved a second Alzheimer’s drug, lecanemab, despite reports of rare brain bleeds linked to use of the drug in some patients.However, the FDA pointed to the dru…
Learn MorePatients, Doctors Await FDA Decision on Experimental Alzheimer’s Drug
THURSDAY, Jan. 5, 2023 (HealthDay News) — Lecanemab: It’s an experimental medication that’s been shown in trials to slow cognitive decline in people with Alzheimer’s disease. It’s also up for accelerated approval by the U.S. Food and Drug Administrat…
Learn MoreOutcomes Worse for Black Patients With Head, Neck Cancer in Clinical Trials
WEDNESDAY, Dec. 28, 2022 (HealthDay News) — For patients with head and neck cancer enrolled in clinical trials, outcomes are worse for Black versus White participants, according to a study published online Dec. 7 in the Journal of the National Cancer…
Learn MoreFemales, Some Minorities Underrepresented in COVID-19 Clinical Trials
TUESDAY, Dec. 13, 2022 (HealthDay News) — Females are underrepresented in COVID-19 treatment trials, while Asian and Black individuals are underrepresented in COVID-19 prevention trials, according to a review published online Dec. 5 in JAMA Internal …
Learn MorePreprint, Peer-Reviewed Pairs of Studies Generally Concordant
MONDAY, Dec. 12, 2022 (HealthDay News) — Characteristics, results, and final interpretations are generally consistent for clinical studies posted as preprints on medRxiv and subsequently published in peer-reviewed journals, according to a study publi…
Learn MoreAntibody Drug Boosts Survival for Type of Advanced Breast Cancer
THURSDAY, Dec. 8, 2022 (HealthDay News) — A relatively new drug is boosting survival rates for women with a specific type of advanced breast cancer who haven’t responded to other treatments, according to a pair of clinical trials.The targeted antibod…
Learn MoreStudy Explores Impact of FDA Approval of Aducanumab on Trial Participation
TUESDAY, Dec. 6, 2022 (HealthDay News) — The U.S. Food and Drug Administration decision to approve aducanumab may have negatively impacted willingness to participate in preclinical Alzheimer disease (AD) trials, according to a study published online …
Learn MoreUna segunda muerte en un ensayo sobre un medicamento experimental para el Alzheimer es preocupante
MARTES, 29 de noviembre de 2022 (HealthDay News) — Ya han muerto dos personas por hemorragias en el cerebro que podrían estar vinculadas con un medicamento experimental para el Alzheimer, lo que pone en duda la seguridad del fármaco.Una mujer de 65 a…
Learn More